• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

钆塞酸二钠增强磁共振成像与 64 层多排 CT 检测肝硬化患者肝细胞癌的个体内比较。

Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the Detection of hepatocellular carcinoma in patients with cirrhosis.

机构信息

Departments of Radiological Sciences, General Surgery, Division of Organ Transplantation, Surgery P. Valdoni, and Statistics, University of Rome Sapienza, Rome, Italy.

出版信息

Radiology. 2010 Sep;256(3):806-16. doi: 10.1148/radiol.10091334.

DOI:10.1148/radiol.10091334
PMID:20720069
Abstract

PURPOSE

To prospectively compare gadoxetate disodium-enhanced magnetic resonance (MR) imaging with multiphasic 64-section multidetector computed tomography (CT) in the detection of hepatocellular carcinoma (HCC) in patients with cirrhosis.

MATERIALS AND METHODS

Institutional review board approval and informed patient consent were obtained for this prospective study. Fifty-eight patients (39 men, 19 women; mean age, 63 years; age range, 35-84 years) underwent gadoxetate disodium-enhanced MR imaging and multiphasic 64-section multidetector CT. The imaging examinations were performed within 30 days of each other. The two sets of images were qualitatively analyzed in random order by three independent readers in a blinded and retrospective fashion. Using strict diagnostic criteria for HCC, readers classified all detected lesions with use of a four-point confidence scale. The reference standard was a combination of pathologic proof, conclusive imaging findings, and substantial tumor growth at follow-up CT or MR imaging (range of follow-up, 90-370 days). The diagnostic accuracy, sensitivity, and positive predictive value were compared between the two image sets. Interreader variability was assessed. The accuracy of each imaging method was determined by using an adjusted modified chi(2) test.

RESULTS

Eighty-seven HCCs (mean size +/- standard deviation, 1.8 cm +/- 1.5; range, 0.3-7.0 cm) were confirmed in 42 of the 58 patients. Regardless of lesion size, the average diagnostic accuracy and sensitivity for all readers were significantly greater with gadoxetate disodium-enhanced MR imaging (average diagnostic accuracy: 0.88, 95% confidence interval [CI]: 0.80, 0.97; average sensitivity: 0.85, 95% CI: 0.74, 0.96) than with multidetector CT (average diagnostic accuracy: 0.74, 95% CI: 0.65, 0.82; average sensitivity: 0.69, 95% CI: 0.59, 0.79) (P < .001 for each). No significant difference in positive predictive value was observed between the two image sets for each reader. Interreader agreement was good to excellent.

CONCLUSION

Compared with multiphasic 64-section multidetector CT, gadoxetate disodium-enhanced MR imaging yields significantly higher diagnostic accuracy and sensitivity in the detection of HCC in patients with cirrhosis.

摘要

目的

前瞻性比较钆塞酸二钠增强磁共振成像(MR)与多期 64 层多层螺旋 CT 在肝硬化患者肝细胞癌(HCC)检测中的作用。

材料与方法

本前瞻性研究获得了机构审查委员会的批准和患者的知情同意。58 例患者(39 名男性,19 名女性;平均年龄 63 岁;年龄范围 35-84 岁)接受了钆塞酸二钠增强 MR 成像和多期 64 层多层螺旋 CT 检查。这两种成像检查在 30 天内完成。三位独立的观察者以随机和盲法回顾的方式对两组图像进行定性分析。使用严格的 HCC 诊断标准,读者使用四点置信度评分对所有检测到的病变进行分类。参考标准是病理学证实、明确的影像学结果以及随访 CT 或 MR 成像(随访时间范围为 90-370 天)中肿瘤的实质性生长的综合。比较了两种图像集的诊断准确性、敏感度和阳性预测值。评估了读者间的变异性。使用调整后的改良卡方检验确定每种成像方法的准确性。

结果

在 58 例患者中的 42 例中,确认了 87 个 HCC(平均大小 +/-标准差,1.8cm +/-1.5;范围,0.3-7.0cm)。无论病变大小如何,所有读者的钆塞酸二钠增强 MR 成像的平均诊断准确性和敏感度均显著高于多排螺旋 CT(平均诊断准确性:0.88,95%置信区间[CI]:0.80,0.97;平均敏感度:0.85,95% CI:0.74,0.96)(每个 P 值均<.001)。对于每个读者,两种图像集的阳性预测值之间没有显著差异。读者间的一致性为良好到极好。

结论

与多期 64 层多层螺旋 CT 相比,钆塞酸二钠增强 MR 成像在肝硬化患者 HCC 的检测中具有更高的诊断准确性和敏感度。

相似文献

1
Intraindividual comparison of gadoxetate disodium-enhanced MR imaging and 64-section multidetector CT in the Detection of hepatocellular carcinoma in patients with cirrhosis.钆塞酸二钠增强磁共振成像与 64 层多排 CT 检测肝硬化患者肝细胞癌的个体内比较。
Radiology. 2010 Sep;256(3):806-16. doi: 10.1148/radiol.10091334.
2
Hepatocellular carcinoma in patients with cirrhosis: qualitative comparison of gadobenate dimeglumine-enhanced MR imaging and multiphasic 64-section CT.肝硬化患者的肝细胞癌:钆贝葡胺增强磁共振成像与64层多期CT的定性比较
Radiology. 2009 Apr;251(1):85-95. doi: 10.1148/radiol.2511080400.
3
Hypervascular hepatocellular carcinomas: detection with gadoxetate disodium-enhanced MR imaging and multiphasic multidetector CT.富含血供的肝细胞癌:钆塞酸二钠增强磁共振成像与多期多排 CT 的检测。
Eur Radiol. 2012 Apr;22(4):845-54. doi: 10.1007/s00330-011-2316-y. Epub 2011 Nov 7.
4
Detection and characterization of focal liver lesions: a Japanese phase III, multicenter comparison between gadoxetic acid disodium-enhanced magnetic resonance imaging and contrast-enhanced computed tomography predominantly in patients with hepatocellular carcinoma and chronic liver disease.检测和描述肝脏局灶性病变:一项日本 III 期、多中心的钆塞酸二钠增强磁共振成像与增强计算机断层扫描对比研究,主要针对肝细胞癌和慢性肝病患者。
Invest Radiol. 2010 Mar;45(3):133-41. doi: 10.1097/RLI.0b013e3181caea5b.
5
Hepatocellular carcinoma in patients with chronic liver disease: comparison of SPIO-enhanced MR imaging and 16-detector row CT.慢性肝病患者的肝细胞癌:超顺磁性氧化铁增强磁共振成像与16排螺旋CT的比较
Radiology. 2006 Feb;238(2):531-41. doi: 10.1148/radiol.2381042193. Epub 2005 Dec 21.
6
Imaging study of early hepatocellular carcinoma: usefulness of gadoxetic acid-enhanced MR imaging.早期肝细胞癌的影像学研究:钆塞酸增强磁共振成像的作用。
Radiology. 2011 Dec;261(3):834-44. doi: 10.1148/radiol.11101840. Epub 2011 Oct 13.
7
Small (≤1-cm) hepatocellular carcinoma: diagnostic performance and imaging features at gadoxetic acid-enhanced MR imaging.小肝癌(≤1cm):钆塞酸增强磁共振成像的诊断性能和影像学特征。
Radiology. 2014 Jun;271(3):748-60. doi: 10.1148/radiol.14131996. Epub 2014 Feb 1.
8
Assessment of arterial hypervascularity of hepatocellular carcinoma: comparison of contrast-enhanced US and gadoxetate disodium-enhanced MR imaging.评估肝细胞癌的动脉血供丰富程度:超声造影与钆塞酸二钠增强磁共振成像的比较。
Eur Radiol. 2012 Jun;22(6):1205-13. doi: 10.1007/s00330-011-2372-3. Epub 2012 Jan 24.
9
Diagnostic performance of gadoxetic acid-enhanced liver MR imaging in the detection of HCCs and allocation of transplant recipients on the basis of the Milan criteria and UNOS guidelines: correlation with histopathologic findings.钆塞酸增强肝脏磁共振成像在检测 HCC 和根据米兰标准和 UNOS 指南分配肝移植受者中的诊断性能:与组织病理学发现的相关性。
Radiology. 2015 Jan;274(1):149-60. doi: 10.1148/radiol.14140141. Epub 2014 Sep 5.
10
Gadoxetate disodium-enhanced magnetic resonance imaging versus contrast-enhanced 18F-fluorodeoxyglucose positron emission tomography/computed tomography for the detection of colorectal liver metastases.钆塞酸二钠增强磁共振成像与对比增强 18F-氟脱氧葡萄糖正电子发射断层扫描/计算机断层扫描在结直肠癌肝转移检测中的比较。
Invest Radiol. 2011 Sep;46(9):548-55. doi: 10.1097/RLI.0b013e31821a2163.

引用本文的文献

1
Gd-EOB-DTPA-enhanced MRI proves advantageous in selecting surgical candidates for patients with early-stage hepatocellular carcinoma: An analysis in terms of oncological outcomes.钆塞酸二钠增强磁共振成像在为早期肝细胞癌患者选择手术候选者方面具有优势:一项基于肿瘤学结局的分析。
ILIVER. 2024 Sep 18;3(4):100117. doi: 10.1016/j.iliver.2024.100117. eCollection 2024 Dec.
2
Optimizing Cabozantinib Dosing in Unresectable Hepatocellular Carcinoma of 7-on/7-off Regimen.优化卡博替尼在不可切除肝细胞癌7天用药/7天停药方案中的剂量
Cancers (Basel). 2025 Apr 10;17(8):1288. doi: 10.3390/cancers17081288.
3
Early Clinical Outcomes of Durvalumab Plus Tremelimumab in Unresectable Hepatocellular Carcinoma: A Real-World Comparison with First-Line or Later-Line Treatment.
度伐利尤单抗联合曲美木单抗治疗不可切除肝细胞癌的早期临床结果:与一线或二线治疗的真实世界比较
Drugs Real World Outcomes. 2024 Dec;11(4):701-710. doi: 10.1007/s40801-024-00458-7. Epub 2024 Oct 10.
4
The comparison of contrast-enhanced ultrasound and gadoxetate disodium-enhanced MRI LI-RADS for nodules ≤2 cm in patients at high risk for HCC: a prospective study.超声造影与钆塞酸二钠增强MRI LI-RADS对肝癌高危患者≤2 cm结节的比较:一项前瞻性研究。
Front Oncol. 2024 May 7;14:1345981. doi: 10.3389/fonc.2024.1345981. eCollection 2024.
5
Clinical usefulness of newly developed prognostic predictive score for atezolizumab plus bevacizumab for hepatocellular carcinoma.新开发的预测评分系统在阿替利珠单抗联合贝伐珠单抗治疗肝细胞癌中的临床应用价值。
Cancer Rep (Hoboken). 2024 Apr;7(4):e2042. doi: 10.1002/cnr2.2042.
6
Clinical features of patients with hepatocellular carcinoma treated with radiofrequency ablation therapy: developing a simple score to determine the need for immune-adjuvant therapy.射频消融治疗肝细胞癌患者的临床特征:建立一个简单的评分来确定免疫辅助治疗的需求。
Clin J Gastroenterol. 2024 Jun;17(3):401-411. doi: 10.1007/s12328-024-01938-7. Epub 2024 Mar 26.
7
Evidence Supporting Diagnostic Value of Liver Imaging Reporting and Data System for CT- and MR Imaging-based Diagnosis of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis.支持肝脏影像报告和数据系统对基于CT和MR成像的肝细胞癌诊断的诊断价值的证据:一项系统评价和荟萃分析。
J Biomed Phys Eng. 2024 Feb 1;14(1):5-20. doi: 10.31661/jbpe.v0i0.2211-1562. eCollection 2024 Feb.
8
Attempt to Establish Prognostic Predictive System for Hepatocellular Carcinoma Using Artificial Intelligence for Assistance with Selection of Treatment Modality.尝试利用人工智能建立肝细胞癌预后预测系统以辅助治疗方式的选择。
Liver Cancer. 2023 May 25;12(6):565-575. doi: 10.1159/000530078. eCollection 2023 Dec.
9
Early detection of hypervascularization in hepatocellular carcinoma (≤2 cm) on hepatic arterial phase with virtual monochromatic imaging: Comparison with low-tube voltage CT.肝细胞癌(≤2cm)肝动脉期虚拟单能量成像下高血管化的早期检测:与低管电压 CT 的比较。
Medicine (Baltimore). 2023 Sep 29;102(39):e34774. doi: 10.1097/MD.0000000000034774.
10
Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter Analysis.阿替利珠单抗联合贝伐单抗治疗与不可切除肝细胞癌患者肌肉量减少的关系:多中心分析
Liver Cancer. 2022 Dec 8;12(3):209-217. doi: 10.1159/000527402. eCollection 2023 Aug.